𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype

✍ Scribed by Jacques Izopet; Corinne Souyris; Karine Sandres-Sauné; Bénédicte Puissant; Martine Obadia; Christophe Pasquier; Jacqueline Puel; Antoine Blancher; Patrice Massip

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
88 KB
Volume
68
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The circulating human immunodeficiency virus type 1 (HIV‐1) population of patients in whom many prior therapy regimens have failed often undergo a shift from a drug‐resistant virus to a wild‐type virus following interruption of treatment. This study analyses the virological and immunological effects of salvage therapy following treatment interruption and a shift from a drug‐resistance genotype. Twenty‐one HIV‐1 infected patients who had genotype reversion by population‐based sequencing after 3 months of treatment interruption were given a new salvage regimen consisting of 3–5 drugs selected according to their treatment history. Seven (33%) of 21 patients who had fewer than 200 HIV‐1 RNA copies/ml until month 12 were defined as virological responders. Four patients were transient responders and 10 were nonresponders. The virological responders were more frequently CDC group A and had higher CD4 + T lymphocyte counts at the time of treatment resumption. The peripheral blood T CD4 + and T CD8 + lymphocyte populations of the patients declined significantly during treatment interruption. Only virological responders showed significant increases in their CD4 + T lymphocyte count 12 months after treatment resumption and these counts rapidly returned to pre‐interruption baseline values in most of these patients. Treatment interruption could be useful for optimising salvage therapy for patients previously given many failing regimens. However, controlled trials are needed to assess the clinical benefit of this strategy. J. Med. Virol. 68:305–310, 2002. © 2002 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Virological and pharmacological factors
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)
✍ Constance Delaugerre; Gilles Peytavin; Stephanie Dominguez; Anne-Genevieve Marce 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Abstract Both highly potent antiretroviral drug rescue multi therapy and treatment interruption (TI) have been suggested to be effective in HIV‐1 infected‐patients with multiple treatment failure. GigHAART‐ANRS 097 was the only randomized trial during which an 8‐week TI was beneficial in heavily

Predicting treatment outcome following 2
Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6
✍ Esther Lukasiewicz; Kristoffer Hellstrand; Johan Westin; Carlo Ferrari; Avidan U 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

We sought to validate FIB-4 using data retrospectively collected from treatment-naive HIV/HCV patients. The original model was adapted in order to use AST and ALT levels expressed as times the upper limit of normality (ϫULN), as follows: (age [yr] ϫ AST [ϫULN]) ϫ 10/((PLT [10 9 /l]) ϫ (ALT [ϫULN]) 1